Tobira Therapeutics Inc. (NASDAQ:TBRA) shares fell 1.4% on Friday . The company traded as low as $11.60 and last traded at $11.70, with a volume of 65,892 shares changing hands. The stock had previously closed at $11.87.

A number of brokerages have recently weighed in on TBRA. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a research report on Wednesday, May 4th. Leerink Swann restated a “buy” rating on shares of Tobira Therapeutics in a research report on Monday, May 2nd. Zacks Investment Research upgraded Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a research report on Saturday, April 23rd. Cantor Fitzgerald began coverage on Tobira Therapeutics in a research report on Wednesday, July 6th. They set a “buy” rating and a $27.00 price objective for the company. Finally, Cowen and Company restated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $20.20.

The company’s 50-day moving average price is $11.52 and its 200 day moving average price is $8.75. The firm’s market capitalization is $220.14 million.

Tobira Therapeutics (NASDAQ:TBRA) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. On average, analysts expect that Tobira Therapeutics Inc. will post ($2.49) earnings per share for the current year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 66,814 shares of the company’s stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $13.04, for a total value of $871,254.56. Following the completion of the transaction, the insider now owns 2,073,022 shares in the company, valued at $27,032,206.88. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP acquired a new position in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned approximately 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.